The influence of mifepristone to caspase 3 expression in adenomyosis

Wang Y, Y Wang, Yushan Wang, Xinwei Jiang, Jiang X, X Jiang, Wang S, S Wang
Clinical and experimental obstetrics & gynecology · 2014 · vol. 41(2) , pp. 154–157 · doi:10.12891/ceog15872014 · PMID:24779241 · W1466955774
article OA: bronze CC0 ⤵ 8 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

Mifepristone treatment significantly increased caspase 3 expression in both eutopic and ectopic endometria of adenomyosis patients compared to placebo, suggesting it initiates cell apoptosis and inhibits disease development.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This paper studied whether mifepristone alters caspase-3 expression, a marker associated with apoptosis, in adenomyosis tissue. Sixty adenomyosis patients were assigned to placebo or to mifepristone at 5, 10, or 15 mg, and caspase-3 expression was measured by immunohistochemistry in eutopic and ectopic endometrial tissues from 40 cases. Compared with placebo, caspase-3 expression was significantly increased in both tissue locations in all mifepristone groups, with no difference between the 10 and 15 mg groups (as described), while higher intensities in both tissue types were reported for 10 and 15 mg versus the 5 mg group. This paper is centrally about adenomyosis — it evaluates how mifepristone influences caspase-3 expression and related apoptosis in eutopic and ectopic adenomyosis endometrium.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue. MATERIALS AND METHODS: Sixty patients were equally divided into four groups. Groups 1, 2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases. RESULTS: Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01). CONCLUSION: Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.
Full text 1,726 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Objective: To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue. Materials and Methods: Sixty patients were equally divided into four groups. Groups 1,2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases. Results: Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01). Conclusion: Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.

Keywords

- Adenomyosis - Apoptosis - Caspase3 - Mifepristone

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Caspase 3 Endometrium Hormone Antagonists Mifepristone Adenomyosis Adenomyosis Adult Caspase 3 Dose-Response Relationship, Drug Endometrium Female Hormone Antagonists Humans Immunohistochemistry Middle Aged Mifepristone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (13)

Cited by (9)

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:29.016410+00:00
License: CC0 · commercial use OK